MARKET

MBRX

MBRX

Moleculin Biotec
NASDAQ
1.430
-0.060
-4.03%
After Hours: 1.390 -0.04 -2.80% 16:59 12/08 EST
OPEN
1.470
PREV CLOSE
1.490
HIGH
1.480
LOW
1.380
VOLUME
59.87K
TURNOVER
0
52 WEEK HIGH
2.330
52 WEEK LOW
0.8170
MARKET CAP
40.94M
P/E (TTM)
-1.6306
1D
5D
1M
3M
1Y
5Y
Moleculin Granted FDA Fast Track Designation Of WP1122 For The Treatment Of Glioblastoma Multiforme
Benzinga · 1d ago
Moleculin Biotech Says FDA Grants Fast Track Designation to Brain Tumor Drug WP1122; Shares Rise
Moleculin Biotech Says FDA Grants Fast Track Designation to Brain Tumor Drug WP1122; Shares Rise
MT Newswires · 1d ago
Celularity, Moleculin Biotech And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 11/29 11:11
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday
Benzinga · 11/22 08:49
BRIEF-Moleculin Reports Third Quarter 2022 Financial Results And Provides Pipeline Update
Reuters · 11/10 22:08
Moleculin Biotech Q3 EPS $(0.30) Down From $(0.15) YoY
Benzinga · 11/10 21:54
Moleculin Biotech GAAP EPS of -$0.30
Seekingalpha · 11/10 21:33
-- Earnings Flash (MBRX) MOLECULIN BIOTECH Posts Q3 Loss $-0.30
-- Earnings Flash (MBRX) MOLECULIN BIOTECH Posts Q3 Loss $-0.30
MT Newswires · 11/10 16:17
More
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The Company's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.

Webull offers kinds of Moleculin Biotech Inc stock information, including NASDAQ:MBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MBRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MBRX stock methods without spending real money on the virtual paper trading platform.